BTG gets positive approval for ZYTIGA

ZYTIGA, the prostate cancer treatment drug developed by specialist healthcare company BTG, has been approved by the European Medicines Agency (EMA), the firm announced on Tuesday morning.

ZYTIGA, the prostate cancer treatment drug developed by specialist healthcare company BTG, has been approved by the European Medicines Agency (EMA), the firm announced on Tuesday morning.

BTG, which develops and commercialises pharmaceutical products, highlighted the announcement by pharmaceuticals group Janssen-Cilag International that the Committee for Medial Products for Human Use (CHMP) of the EMA has "granted a positive opinion recommending approval" of ZYTIGA.

ZYTIGA, otherwise known as abiraterone acetate, is the oral, once-daily medication for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

"If endorsed by the European Commission, the recommendation would expand the indication for ZYTIGA, which is currently approved for use in combination withprednisone/prednisolone to treat men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen."

Janssen expects to receive the regulatory decision from the European Commission in early 2013.

"This positive opinion brings us a step closer to being able to offer ZYTIGA to advanced cancer patients earlier in the course of their disease and fills a previously unmet medical need," said Jane Griffiths, the Chairman of Janssen's Middle-East and African division.

"If approved, the expanded indication will provide a welcome new option for patients with castration-resistant prostate cancer. It could not only give men a chance of extended survival, but may also delay the need for chemotherapy and help to improve their quality of life."

Recommended

Share tips of the week - 12 August
Share tips

Share tips of the week - 12 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
12 Aug 2022
Britain’s ten most-hated shares – w/e 9 August
Stocks and shares

Britain’s ten most-hated shares – w/e 9 August

Rupert Hargreaves looks at Britain's ten most-hated shares, and what short-sellers are looking at now.
10 Aug 2022
Aviva: One for income investors to tuck away
Share tips

Aviva: One for income investors to tuck away

Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. R…
10 Aug 2022
Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022

Most Popular